Jump to content

Precigen

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Cyfal (talk | contribs) at 16:52, 3 May 2020 (spelling (Wikipedia:Typo Team)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Precigen, Inc.
Nasdaq: PGEN
Russell 2000 Component
IndustryBiotechnology
FoundedMay 21, 1998; 26 years ago (1998-05-21)
Headquarters
Germantown
Websiteprecigen.com

Precigen, Inc (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.[1][2] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[3]

History

In 2015, Intrexon purchased Oxitec, a maker of gene drive technology for $160 million.[4] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.[5][6] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[7][8] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.[6]

References

  1. ^ "Intrexon Corporation: Private Company Information". Bloomberg. Retrieved 2017-06-26.
  2. ^ "Intrexon Corp (XON) Company Profile". Reuters.com. Retrieved 2017-06-26.
  3. ^ "FAQ | Intrexon". Intrexon InvestorRoom. Retrieved 2018-03-28.
  4. ^ Nickel, Rod (15 September 2015). "Market turbulence or not, North American investors plow into farm tech". Reuters. Retrieved 9 October 2015.
  5. ^ "PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS". FDA. Retrieved 6 April 2020.
  6. ^ a b Gilgore, Sara (6 January 2020). "Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug". American City Business Journals. Retrieved 6 April 2020.
  7. ^ "INTREXON CORPORATION IS NOW PRECIGEN, INC". Precigen. Retrieved 6 April 2020.
  8. ^ Helmstetter, Micheal (30 March 2020). "The Promise And Fear Of Gene Editing". Forbes. Retrieved 6 April 2020.

Official website

Retrieved from "https://en.wikipedia.org/w/index.php?title=Precigen&oldid=954663275"